drugset
drugset / Trial / NCT01853982

Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia

NCT01853982 ↗

Phase 3 Terminated 4 enrolled Merck & Co., Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase 3, multicenter, prospective, randomized, open-label, study to compare the safety and efficacy of intravenous (IV) ceftolozane/tazobactam with that of IV piperacillin/tazobactam in the treatment of ventilator-associated pneumonia (VAP) in adult participants .

Timeline

Start
2013-06-14
Primary completion
2013-11-20
Completion
2013-12-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ceftolozane Small molecule 2000 mg Intravenous
Comparator Piperacillin Small molecule 4000 mg Intravenous
Subject Tazobactam Small molecule 500 mg Intravenous
Subject Tazobactam Small molecule 1000 mg Intravenous

Indications

No indication recorded.